Burlaka Anton, Zemskov Serhii, Bezverkhnyi Volodymyr, Rozhkova Veronika, Zvirych Vitalii, Mykhailo Dupyk, Mykytyuk Artem, Pavliuk Romanna, Skyba Volodymyr
Department of Surgical Oncology, National Cancer Institute, Kiev, Ukraine.
Bogomolets National Medical University, Kiev, Ukraine.
J Gastrointest Cancer. 2025 May 14;56(1):119. doi: 10.1007/s12029-025-01220-0.
The assessment of resectability in patients with colorectal cancer (CRC) and multiple liver metastases is primarily a technical decision. However, in cases with unfavourable tumor biology, the clinical benefit of surgery remains limited. Further research is needed to identify additional factors influencing oncological outcomes in these patients to better guide the decision-making process. The aim of this study was to investigate the association of tumor burden score (TBS) and oncological outcome in CRC patients with multiple bilobar metastases.
Five hundred twenty-one consecutive patients who underwent liver resections for CRC liver metastases between January 2002 and January 2024 were identified from the National Cancer Institute (Kyiv, Ukraine) prospective database and analysed retrospectively.
The median and 5-year overall survival in cohorts with TBS clusters < 3, ≥ 3-9 and ≥ 9 was 116.2 months, 50.3 months and 29.7 months; and 75.7%, 42.4% and 41.6%, respectively (P < 0.001). TBS index has shown high prognostic specificity and sensitivity for postoperative morbidity with AUC 0.97 on the ROC curve. The multivariate Cox regression model has shown that the TBS clusters have a significant negative impact on overall survival particularly in cohorts with TBS ≥ 3-9 (HR: 2.8, 95% CI: 1.7-4.8, P = 0.0001) and TBS ≥ 9 (HR: 1.4, 95% CI: 1.31-1.46, P = 0.005).
In this Ukranian population-based study of patients with resectable CRC liver metastases, high TBS was associated with poorer overall survival.
评估结直肠癌(CRC)合并多发肝转移患者的可切除性主要是一项技术决策。然而,在肿瘤生物学特性不利的情况下,手术的临床获益仍然有限。需要进一步研究以确定影响这些患者肿瘤学结局的其他因素,从而更好地指导决策过程。本研究的目的是调查肿瘤负荷评分(TBS)与多发双侧叶转移CRC患者肿瘤学结局之间的关联。
从乌克兰基辅国立癌症研究所前瞻性数据库中识别出2002年1月至2024年1月期间因CRC肝转移接受肝切除的521例连续患者,并进行回顾性分析。
TBS分组<3、≥3 - 9和≥9的队列中,中位总生存期和5年总生存期分别为116.2个月、50.3个月和29.7个月;以及75.7%、42.4%和41.6%(P<0.001)。TBS指数对术后发病率显示出高预后特异性和敏感性,ROC曲线上的AUC为0.97。多变量Cox回归模型显示,TBS分组对总生存期有显著负面影响,尤其是在TBS≥3 - 9(HR:2.8,95%CI:1.7 - 4.8,P = 0.0001)和TBS≥9(HR:1.4,95%CI:1.31 - 1.46,P = 0.005)的队列中。
在这项基于乌克兰人群的可切除CRC肝转移患者研究中,高TBS与较差的总生存期相关。